Hexarelin
Hexarelin Acetate
The strongest GH secretagogue - with cardioprotective effects
Hexarelin produces the largest GH release of any secretagogue and has unique cardioprotective properties. More potent than ipamorelin but with a less selective profile.
Admin routes
Subcutaneous, Intravenous
Popularity
Medium
Side effects
Generally mild
AU vendors
0 rated
✓Key benefits
📈What to expect
Strong GH pulse; improved sleep and recovery
Increased appetite (ghrelin activation); muscle fullness
Peak GH response; body composition changes
GH response begins to attenuate; cycle off
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
GH stimulation
100–200 mcg
Once or twice daily
4–8 weeks (cycle to avoid desensitisation)
Cardioprotection
100 mcg
Once daily
4–8 week cycles
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|Phase 2 clinical trials - extensive preclinical data
Overview
Hexarelin is a synthetic hexapeptide GH secretagogue that produces the strongest growth hormone release of any peptide in its class. It was one of the first GHRPs studied clinically and remains notable for its unique cardioprotective effects - it binds to cardiac receptors (CD36) independently of its GH-releasing action, providing direct heart protection.
⚙️How it works
Binds to ghrelin (GHS-R1a) receptors on pituitary somatotrophs with high affinity, triggering strong GH release. Also binds to CD36 receptors in cardiac tissue, providing cardioprotective effects independent of GH action. Unlike ipamorelin, hexarelin does increase cortisol and prolactin to some degree, and GH response attenuates (desensitises) with prolonged daily use.
⚡Side effects
📅Research history
Synthesised as an analog of GHRP-6 with enhanced potency
Clinical trials demonstrate strongest GH release of any secretagogue
Cardioprotective effects via CD36 receptor binding discovered
Used in research for cardiac ischaemia protection
Niche use for short GH-boosting cycles and cardiac research
Desensitisation concern
Hexarelin's major limitation is rapid GH-release desensitisation - typically within 4–8 weeks of daily use, the pituitary becomes less responsive. This is more pronounced with hexarelin than ipamorelin. Most protocols cycle it 4 weeks on, 4 weeks off to maintain effectiveness.
Cardioprotective effects
Hexarelin's binding to CD36 receptors in the heart is unique among GH secretagogues. Research has shown it reduces cardiac fibrosis, protects against ischaemia-reperfusion injury, and improves cardiac output - effects that persist even when GH release has desensitised. This makes hexarelin of interest beyond just GH optimisation.
References
- [1]Broglio F, et al. 'Effects of acute and prolonged hexarelin administration on GH secretion.' European Journal of Endocrinology, 2002.
- [2]Locatelli V, et al. 'Hexarelin and growth hormone releasing substances.' Growth Hormone & IGF Research, 1999.
Frequently asked questions
Related peptides
Community experiences
Share your experience with Hexarelin. Effects, side effects, protocol details - help others make informed decisions.
No community reviews yet. Be the first to share your experience with Hexarelin.
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for Hexarelin.
Open CalculatorDisclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.